Home »

Lpath to Present at the 2013 JMP Healthcare Conference on July 9

SAN DIEGO, CA — (Marketwired) — 07/03/13 — Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive-lipid-targeted therapeutics, today announced that it will participate in the JMP Securities Healthcare Conference in New York, taking place July 9-10, 2013. President and Chief Executive Officer Scott R. Pancoast will give his presentation on Tuesday, July 9, 2013 at 2:30 p.m. EDT (11:30 a.m. PDT). He will discuss the company-s pathway to regulatory approval and commercialization of its no

Lpath Granted Key European and U.S. Patents Related to Anti-Cancer Drug Program, ASONEP

Patents Provide Coverage for Lpath-s Anti-S1P Antibody in the Treatment of a Wide Variety of Hyperproliferative Disorders, Including Cancer

Lpath to Present at ROTH Capital Partners 25th Annual Growth Stock Conference on March 19, 2013

SAN DIEGO, CA — (Marketwire) — 03/12/13 — Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, has been invited to present at the ROTH Capital Partners 25th Annual Growth Stock Conference being held on March 17-20, 2013, at The Ritz Carlton in Dana Point, Calif.Lpath President and CEO Scott Pancoast is scheduled to present on Tuesday, March 19, 2013 at 1:00 p.m. Pacific time, with one-on-one meetings held throughout the day. He will discuss the company-s

Lpath Signs Collaboration and License Agreement With Provista Diagnostics to Develop Cancer Diagnostics

SAN DIEGO, CA — (Marketwire) — 03/06/13 — Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, has signed a collaboration and license agreement to develop cancer diagnostics with Provista Diagnostics, Inc. a leader in molecular cancer diagnostics and a CLIA-accredited reference laboratory.The collaboration will focus on the bioactive lipid lysophosphatidic acid (LPA), with the agreement granting Provista an exclusive license to Lpath-s murine LPA antibodi

Lpath to Present Data at Arrowhead-s 3rd Annual Traumatic Brain Injury Conference on March 7, 2013

SAN DIEGO, CA — (Marketwire) — 02/25/13 — Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, has been invited to present data from its Lpathomab program in models of central nervous system injury, including traumatic brain injury (TBI), at Arrowhead-s 3rd Annual Traumatic Brain Injury Conference.Lpathomab is a first-in-class monoclonal antibody that binds to and neutralizes lysophosphatidic acid (LPA), a bioactive lipid that has been implicated in neuro

Lpath Promotes Leigh Hsu, Ph.D., to Vice President of Corporate Development

SAN DIEGO, CA — (Marketwire) — 02/13/13 — Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, has promoted Leigh Hsu, Ph.D., to the new position of vice president of corporate development.Dr. Hsu has more than 13 years of business-development experience in the biotech industry. Prior to joining Lpath in 2008 as its senior director of business development, he held positions of increasing responsibility at ACADIA Pharmaceuticals and Collateral Therapeutics

Lpath Sets Investor Update Conference Call for Thursday, January 3, 2013 at 4:30 p.m. ET

SAN DIEGO, CA — (Marketwire) — 12/26/12 — Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, will hold a conference call on Thursday, January 3, 2013 at 4:30 p.m. Eastern time to provide an update on its Nexus Phase 2 trial for iSONEP, an ocular drug candidate, as well as outline the company-s 2013 objectives.Lpath President and CEO Scott Pancoast will host the presentation, followed by a question-and-answer period.Date: Thursday, January 3, 2013
Time:

Lpath Announces Pricing of Public Offering of Common Stock

SAN DIEGO, CA — (Marketwire) — 12/14/12 — Lpath, Inc. (NASDAQ: LPTN), today announced that it is selling 2,366,000 shares of its common stock at a price to the public of $5.00 per share. The gross proceeds from the sale of the shares, before deducting the underwriting discount and estimated offering expenses payable by it, are expected to be approximately $11.8 million.Lpath intends to use the net proceeds from this offering for research and development activities, operating costs, capital e

Lpath Announces Proposed Public Offering of Common Stock

SAN DIEGO, CA — (Marketwire) — 12/13/12 — Lpath, Inc. (NASDAQ: LPTN) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be complete, or as to the actual size or terms of the offering. Summer Street Research Partners is acting as sole book-running manager for the offering.The securities described above are being offered

Lpath Granted Key European Patent Related to iSONEP Drug Program

New Patent Provides Coverage for Lpath-s Anti-S1P Antibody, Sonepcizumab, in the Treatment of a Wide Variety of Ocular Disorders

Analytics

© 2020 88Finance. All Rights Reserved. Log in - Copyright by LayerMedia


Blogverzeichnis - Blog Verzeichnis bloggerei.de Blog Top Liste - by TopBlogs.de